[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 62, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 885600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 677758, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 402304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 45625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.3, "open": 8.05, "dayLow": 8.05, "dayHigh": 8.05, "regularMarketPreviousClose": 8.3, "regularMarketOpen": 8.05, "regularMarketDayLow": 8.05, "regularMarketDayHigh": 8.05, "beta": -0.056, "volume": 400, "regularMarketVolume": 400, "averageVolume": 3361, "averageVolume10days": 3170, "averageDailyVolume10Day": 3170, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 5.52, "fiftyTwoWeekHigh": 16.75, "fiftyDayAverage": 11.96502, "twoHundredDayAverage": 9.473055, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 43936873, "bookValue": 4.111, "priceToBook": 1.958161, "netIncomeToCommon": -198916000, "52WeekChange": -0.31330472, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 8.05, "recommendationKey": "none", "totalCash": 422728992, "totalCashPerShare": 4.576, "ebitda": -184059008, "totalDebt": 506000, "quickRatio": 10.371, "currentRatio": 10.614, "totalRevenue": 33594000, "debtToEquity": 0.134, "revenuePerShare": 0.373, "returnOnAssets": -0.29273, "returnOnEquity": -0.47369, "grossProfits": 33594000, "freeCashflow": -108734752, "operatingCashflow": -154156992, "revenueGrowth": 8.898, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -0.85888, "financialCurrency": "USD", "symbol": "NAMSW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "regularMarketTime": 1740164820, "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "cryptoTradeable": false, "regularMarketChangePercent": -3.012048, "regularMarketPrice": 8.05, "marketState": "REGULAR", "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 3361, "fiftyTwoWeekLowChange": 2.5300002, "fiftyTwoWeekLowChangePercent": 0.45833337, "fiftyTwoWeekRange": "5.52 - 16.75", "fiftyTwoWeekHighChange": -8.7, "fiftyTwoWeekHighChangePercent": -0.519403, "fiftyTwoWeekChangePercent": -31.330473, "fiftyDayAverageChange": -3.91502, "fiftyDayAverageChangePercent": -0.32720548, "twoHundredDayAverageChange": -1.4230547, "twoHundredDayAverageChangePercent": -0.1502213, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-02-21", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612967400000, "regularMarketChange": -0.25, "regularMarketDayRange": "8.05 - 8.05", "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]